Appl. No. 10/535,508 Attv. Ref.: 620-371

Amendment April 1, 2008

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

1. (Currently Amended) A method of treatment of an extracorporeal organ that

is a donated transplantation organ and is outside the donor's body or isolated organ of a

patient that is inside or attached to a patient's body but is isolated from the patient's

blood supply, said method comprising contacting the extracorporeal organ or the

isolated organ with a composition including a metal carbonyl compound or

pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable

carrier wherein the metal carbonyl or pharmaceutically acceptable salt thereof makes

available carbon monoxide to limit post-ischaemic damage to said extracorporeal organ

or said isolated organ.

Claim 2. (Canceled)

(Original) A method according to claim 1 wherein said metal carbonyl makes

CO available by at least one of the following means:

1) CO derived by dissociation of the metal carbonyl is present in the composition

in dissolved form;

2) on contact with a solvent the metal carbonyl releases CO;

3) on contact with a tissue, organ or cell the metal carbonyl releases CO;

4) on irradiation, the metal carbonyl releases CO.

- 2 -

Appl. No. 10/535,508

Atty. Ref.: 620-371

Amendment April 1, 2008

4. (Currently Amended) A method according to claim 1 wherein treatment is of

said organ is extracorporeal organ.

5. (Currently Amended) A method according to claim 1 wherein treatment is of

said isolated organ is inside or attached to the body but isolated from the blood supply.

6. (Previously Presented) A method according to claim 1 wherein the contacting

step includes perfusing said organ with said composition.

7. (Previously Presented) A method according to claim 1 wherein the metal

carbonyl is a compound of the formula $M(CO)_xA_y$ where x is at least one, y is at least

one, M is a metal, the or each A is an atom or group bonded to M by an ionic, covalent

or coordination bond but is not CO, and in the case where y>1 each A may be the same

or different, or a pharmaceutically acceptable salt of such a compound.

8. (Previously Presented) A method according to claim 7 wherein M is a

transition metal.

9. (Previously Presented) A method according to claim 7, wherein A is selected

from neutral or anionic ligands such as halide or derived from Lewis bases and having

N, P, O, S or C as the coordinating atom.

10. (Currently Amended) A method according to claim 1 wherein the metal

carbonyl compound has the formula

 $M(CO)_x A_y B_z$ where

- 3 -

Appl. No. 10/535,508 Atty. Ref.: 620-371 Amendment April 1, 2008 M is Fe, Co or Ru, x is at least one, y is at least one, z is zero or at least one, each A is a ligand other than CO and is monodentate or polydentate with respect to M and is selected from the amino acids alanine, arginine, asparagines, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine,

Roberto Angelo MOTTERLINI

Roberto Angelo MOTTERLINI Appl. No. 10/535,508 Atty. Ref.: 620-371 Amendment April 1, 2008

> leucine, lysine, methionine, phenylalanine, proline, serine, threonine, Tryptophan, Tyrosine, Valine, $[O(CH_2COO)_2]^{2-}$ and [NH(CH₂COO)₂]²⁻, and

B is optional and is a ligand other than CO.

Claims 11 - 15. (Cancelled)

16. (new) A method of treatment of an extracorporeal organ that is a donated transplantation organ and is outside the donor's body, said method comprising

Appl. No. 10/535,508

Attv. Ref.: 620-371

Amendment April 1, 2008

contacting the extracorporeal organ with a composition including a metal carbonyl

compound or pharmaceutically acceptable salt thereof and at least one

pharmaceutically acceptable carrier, at a temperature in the range of 2 to 10°C, wherein

the metal carbonyl makes available carbon monoxide to limit post-ischaemic damage of

said extracorporeal organ.

17. (new) A method according to claim 16 wherein said metal carbonyl makes

CO available by at least one of the following means:

1) CO derived by dissociation of the metal carbonyl is present in the composition

in dissolved form;

2) on contact with a solvent the metal carbonyl releases CO;

3) on contact with a tissue, organ or cell the metal carbonyl releases CO;

4) on irradiation, the metal carbonyl releases CO.

18. (new) A method according to claim 16 wherein the contacting step includes

perfusing said organ with said composition.

19. (new) A method according to claim 16 wherein the metal carbonyl is a

compound of the formula $M(CO)_xA_v$ where x is at least one, y is at least one, M is a

metal, the or each A is an atom or group bonded to M by an ionic, covalent or

- 6 -

Appl. No. 10/535,508

Attv. Ref.: 620-371

Amendment April 1, 2008

coordination bond but is not CO, and in the case where y>1 each A may be the same or

different, or a pharmaceutically acceptable salt of such a compound.

20. (new) A method according to claim 19 wherein M is a transition metal.

21. (new) A method according to claim 19, wherein each A is separately selected

from neutral or anionic ligands.

22. (new) A method of claim 21 wherein each A is separately a halide or is

derived from a Lewis base and has N, P, O, S or C as the coordinating atom.

23. (new) A method according to claim 16 wherein the metal carbonyl compound

has the formula

 $M(CO)_x A_v B_z$ where

M is Fe, Co or Ru,

x is at least one,

y is at least one,

z is zero or at least one,

each A is a ligand other than CO and is monodentate or polydentate with

respect to M and is alanine, arginine, asparagines, aspartic acid, cysteine, glutamic

acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine,

- 7 -

Roberto Angelo MOTTERLINI Appl. No. 10/535,508 Atty. Ref.: 620-371 Amendment April 1, 2008

proline, serine, threonine, tryptophan, tyrosine, valine, $[O(CH_2COO)_2]^{2-}$ or $[NH(CH_2COO)_2]^{2-}$, and

B is optional and is a ligand other than CO.